When to Stop Apixaban Before Liver Biopsy
Stop apixaban 2 days (48 hours) before percutaneous liver biopsy. This is the standard recommendation for direct oral anticoagulants (DOACs) including apixaban before high-bleed-risk procedures 1.
Evidence-Based Timing
The British Society of Gastroenterology 2020 guidelines explicitly state that direct oral anticoagulant drugs should be stopped for 2 days prior to the day of the biopsy 1. This recommendation is reinforced by the FDA label for apixaban, which specifies that apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 2. Percutaneous liver biopsy falls into this high-bleed-risk category.
The American College of Chest Physicians 2022 guidelines corroborate this approach, recommending:
- 2 days off apixaban before high-bleed-risk procedures (which includes liver biopsy)
- 1 day off for low-to-moderate-bleed-risk procedures 3
Why 2 Days is Sufficient
Unlike warfarin (which requires 5 days of interruption), apixaban has a rapid offset of action with a half-life of approximately 12 hours 3. Two days allows for 4-5 half-lives to elapse, ensuring minimal residual anticoagulant effect at the time of the procedure—critical for high-bleed-risk interventions like liver biopsy.
Important Considerations
Renal function does NOT alter apixaban timing for liver biopsy. The 2-day interruption applies regardless of kidney function 1, 3. This differs from dabigatran, which requires extended interruption (up to 4 days) in patients with reduced creatinine clearance.
Bridging anticoagulation is NOT recommended. The guidelines explicitly state that bridging with heparin during the 24-48 hours after stopping apixaban is not generally required due to the drug's rapid onset and offset 2.
Resumption After Biopsy
Restart apixaban at least 24 hours after the procedure once adequate hemostasis has been established 2. The FDA label emphasizes restarting "as soon as adequate hemostasis has been established," which typically means 24-48 hours post-procedure for high-bleed-risk interventions.
Special Circumstances
If the patient has liver cirrhosis with portal hypertension or coagulopathy, strongly consider a transvenous (transjugular) approach instead of percutaneous biopsy, as these patients are at particularly high risk of bleeding 1. The same 2-day apixaban interruption applies, but the procedural approach should be modified.
For patients with platelet count <50 × 10⁹/L, a transvenous approach is strongly recommended regardless of anticoagulation status 1.
Critical Pitfall to Avoid
Do not confuse apixaban management with warfarin management. Warfarin requires 5 days of interruption with INR monitoring, while apixaban requires only 2 days with no monitoring needed 1. The rapid pharmacokinetics of DOACs fundamentally change perioperative management compared to vitamin K antagonists.